Solutions for Accelerating Infectious Disease Research

Despite their biological simplicity, viruses are powerful pathogens with the demonstrated ability to greatly affect human society. Viral pandemics, such as the most recent COVID-19 pandemic, have the capacity to cause millions of deaths.¹ Infectious viral diseases are difficult to study and treat because many viruses present clinically in a similar manner despite having significantly different genomic structures, modes of infection, and transmissibility. Furthermore, viruses can mutate regularly, resulting in novel strains that evade or attenuate the effectiveness of existing vaccines and treatment strategies.²

At the same time, the threat posed by viruses is fueling research into how they work and how to combat them. The COVID-19 pandemic provided the impetus for many landmark breakthroughs, ranging from new monoclonal antibody therapeutics to pioneering mRNA vaccine technology. It also spurred researchers to look for approaches with broader tropism, such as pan-coronavirus agents.¹  

These initiatives are powered by highly specialized biochemical tools necessary to unravel the unique biochemistry physiology, and pathology of viruses. These tools, sourced from companies like Sino Biological, include recombinant viral proteins, antibodies, antibody pairs, ELISA kits, and cDNA clones,
and support antiviral drug discovery, vaccine research, and diagnostics development. Sino Biological, in particular, offers scientists one of the largest recombinant viral antigen libraries and can also provide custom services to create tools to answer new questions.

Viral outbreak frequency and magnitude is expected to increase as the 21^st century continues.¹ Scientists rely on companies such as Sino Biological to provide a comprehensive array of solutions as they prepare to meet this challenge.

Learn more about how the latest reagents and tools can accelerate infectious disease research.

What reagents do you use to study viruses in your lab?

Submit Your Answer